Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm
Inspira Technologies (NASDAQ: IINN) announced two leadership changes on October 21, 2025: the appointment of Mike Hershkovitz as Vice President of Global Sales and the appointment of Sivan Matza as an independent member of the company’s board of directors. Ms. Matza will join the compensation, audit and financial statement examination committees and succeeds Limor Rosen, who is stepping down. Mr. Hershkovitz, based in the United States, brings nearly two decades of commercial experience including senior roles at Johnson & Johnson and will lead global sales and hospital adoption efforts. The company highlighted these additions as strategic to support governance and global commercialization as Inspira advances its diagnostic and life-support technologies.
Inspira Technologies (NASDAQ: IINN) ha annunciato due cambiamenti nella leadership il 21 ottobre 2025: la nomina di Mike Hershkovitz a vicepresidente delle vendite globali e la nomina di Sivan Matza come membro indipendente del consiglio di amministrazione dell'azienda. La signora Matza entrerà nei comitati di compensazione, audit e esame dei rendiconti finanziari e sostituisce Limor Rosen, che si dimette. Il signor Hershkovitz, con sede negli Stati Uniti, porta quasi due decenni di esperienza commerciale, tra cui ruoli senior in Johnson & Johnson, e guiderà le vendite globali e l'adozione negli ospedali. L'azienda ha evidenziato queste aggiunte come strategiche per supportare la governance e la commercializzazione globale mentre Inspira avanza con le sue tecnologie diagnostiche e di supporto vitale.
Inspira Technologies (NASDAQ: IINN) anunció dos cambios de liderazgo el 21 de octubre de 2025: el nombramiento de Mike Hershkovitz como vicepresidente de ventas globales y el nombramiento de Sivan Matza como miembro independiente del consejo de administración de la empresa. La Sra. Matza se unirá a los comités de compensación, auditoría y examen de estados financieros y sucede a Limor Rosen, quien se retira. El Sr. Hershkovitz, con sede en Estados Unidos, aporta casi dos décadas de experiencia comercial, incluyendo cargos sénior en Johnson & Johnson, y dirigirá las ventas globales y la adopción en hospitales. La empresa destacó estas incorporaciones como estratégicas para apoyar la gobernanza y la comercialización global a medida que Inspira avanza con sus tecnologías de diagnóstico y apoyo a la vida.
Inspira Technologies (NASDAQ: IINN)은 2025년 10월 21일 두 가지 리더십 변화를 발표했습니다: 글로벌 세일즈 부문 부사장으로의 마이크 허시코비츠(Mike Hershkovitz) 임명 및 이사회 독립 이사로서 시반 마차(Sivan Matza)의 임명입니다. 마차 이사는 보상, 감사 및 재무제표 감사 위원회에 합류하고 물러나는 Limor Rosen을 대체합니다. 미국에 본사를 둔 허시코비츠는 Johnson & Johnson에서의 고위직을 포함해 거의 20년의 상업적 경력을 바탕으로 글로벌 판매와 병원 채택 노력을 이끌 것입니다. 회사는 이러한 보강이 거버넌스와 글로벌 상용화를 지원하기 위한 전략적 조치로 강조했으며, Inspira가 진단 및 생명유지 기술을 개발함에 따라.
Inspira Technologies (NASDAQ : IINN) a annoncé deux changements de direction le 21 octobre 2025 : la nomination de Mike Hershkovitz au poste de vice-président des ventes mondiales et la nomination de Sivan Matza comme membre indépendant du conseil d'administration de l'entreprise. Mme Matza rejoindra les comités de rémunération, d'audit et d'examen des états financiers et succède à Limor Rosen, qui se retire. M. Hershkovitz, basé aux États-Unis, apporte près de deux décennies d'expérience commerciale, notamment à des postes de direction chez Johnson & Johnson, et dirigera les ventes mondiales et l'adoption hospitalière. L'entreprise a qualifié ces ajouts de stratégiques pour soutenir la gouvernance et la commercialisation mondiale à mesure qu'Inspira fait progresser ses technologies de diagnostic et de maintien en vie.
Inspira Technologies (NASDAQ: IINN) gab am 21. Oktober 2025 zwei Führungswechsel bekannt: die Ernennung von Mike Hershkovitz zum Vice President Global Sales und die Ernennung von Sivan Matza als unabhängiges Mitglied des Vorstands des Unternehmens. Frau Matza wird den Vergütungs-, Audit- und Prüfungsausschuss des Abschlussberichts beitreten und Limor Rosen ablösen, die zurücktritt. Herr Hershkovitz, mit Sitz in den USA, bringt fast zwei Jahrzehnte kommerzielle Erfahrung, einschließlich leitender Positionen bei Johnson & Johnson, mit und wird den globalen Vertrieb und die Einführung in Krankenhäusern leiten. Das Unternehmen hob diese Ergänzungen als strategisch hervor, um Governance und weltweite Kommerzialisierung zu unterstützen, während Inspira seine Diagnostik- und Lebensunterstützungstechnologien vorantreibt.
Inspira Technologies (NASDAQ: IINN) أعلنت عن تغييرين في القيادة بتاريخ 21 أكتوبر 2025: تعيين Mike Hershkovitz كنائب رئيس للمبيعات العالمية وتعيين Sivan Matza كعضو مستقل في مجلس إدارة الشركة. ستنضم السيدة ماتزا إلى لجان التعويض والمراجعة والتدقيق وفحص البيانات المالية وستحل محل Limor Rosen، التي ستتقاعد. السيد هيرشكوفيتز، ومقره الولايات المتحدة، يجلب ما يقرب من عقدين من الخبرة التجارية بما في ذلك مناصب عليا في Johnson & Johnson وسيقود المبيعات العالمية واعتماد المستشفيات. أشارت الشركة إلى أن هذه الإضافات استراتيجية لدعم الحوكمة والتسويق العالمي أثناء تقدم Inspira تقنياتها التشخيصية وتقنيات دعم الحياة.
Inspira Technologies (NASDAQ: IINN) 于 2025年10月21日 宣布了两项领导层变动：任命 Mike Hershkovitz 为全球销售副总裁，以及任命 Sivan Matza 为公司董事会的独立成员。Matza 女士将加入薪酬、审计及财务报表审查委员会，并接替即将辞任的 Limor Rosen。Hershkovitz 总部位于美国，凭借近二十年的商业经验（包括在 Johnson & Johnson 的高级职位），将领导全球销售和医院采纳工作。公司强调，这些增补对治理和全球商业化具有战略意义，助力 Inspira 在诊断与生命维持技术方面的推进。
- Appointed Mike Hershkovitz as Vice President of Global Sales
- Appointed Sivan Matza as independent board member
- Matza assigned to compensation, audit, and financial committees
- Hershkovitz brings nearly two decades of commercial med-tech experience
- Board turnover: Limor Rosen is stepping down from the board
RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors of the Company (the “Board”). The Board appointed Ms. Matza to serve as an independent director of the Company until the next annual general meeting of the Company’s shareholders. Ms. Matza will also serve as a member of the Board’s compensation committee, audit committee and financial statement examination committee. Ms. Matza will succeed Ms. Limor Rosen, who is stepping down from the Board.
Ms. Sivan Matza is a Director at a leading international investment management firm overseeing tens of billions of dollars in assets. Her extensive experience in global finance, regulation and accounting strengthens Inspira’s governance framework as the Company accelerates its commercial expansion.
Mr. Mike Hershkovitz, based in the United States, has been appointed Vice President of Global Sales. Mr. Hershkovitz brings nearly two decades of leadership in U.S. and international healthcare markets, including senior commercial roles at Johnson & Johnson and other global med-tech organizations. He will lead Inspira’s sales strategy and hospital adoption initiatives worldwide.
Dagi Ben-Noon, CEO of Inspira Technologies, commented: “The addition of Sivan and Mike to our leadership team is a strategic step that meaningfully enhances Inspira’s capabilities. Sivan’s experience in international finance and regulation from a top-tier firm is an invaluable asset as we expand our operations and strengthen our governance.
In parallel, Mike’s proven leadership in sales and commercial management, including his tenure at Johnson & Johnson, together with his strong understanding of the med-tech industry, will drive our commercial strategy and speed the adoption of our technologies in hospitals worldwide. Their combined expertise is a powerful catalyst for Inspira’s next phase of growth and execution.”
The Company also extended its appreciation to Ms. Limor Rosen, who is stepping down from the Board of Directors.
“We thank Limor for her contribution and commitment to Inspira’s vision and wish her continued success and welcome Sivan to the Board,” stated Tal Parnes, chairman of the Board.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s U.S. Food and Drug Administration -cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company’s recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the reinforcement of its global commercialization and governance following the new appointments, the strengthening of the Company’s governance framework as the Company accelerates its commercial expansion, the potential of the appointments in leading the Company’s commercial strategy and acceleration of its technology’s adoption in hospitals and the combined expertise serving as a powerful catalyst that will bolster the Company as it enters its next phase of accelerated growth and execution. These forward-looking statements and their implications are based solely on the current expectations of the Company’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC’s website at www.sec.gov.
Company Contact
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
This press release is a corrected version of a previous version of the same release which included an error in the release title
FAQ
What leadership appointments did Inspira announce on October 21, 2025 (IINN)?
What will Mike Hershkovitz oversee as Inspira VP of Global Sales (IINN)?
Which board committees will Sivan Matza join at Inspira (IINN)?
When did Inspira make these management and board changes (IINN)?
Who is leaving the Inspira board after the October 21, 2025 announcement (IINN)?
